《新型冠状病毒肺炎疫情期间乳腺癌合理化诊疗指南》解读

黎立喜; 马飞

doi:10.3969/j.issn.1000-8179.2020.08.404

《新型冠状病毒肺炎疫情期间乳腺癌合理化诊疗指南》解读

doi: 10.3969/j.issn.1000-8179.2020.08.404

黎立喜,
马飞^,

国家癌症中心/国家肿瘤临床医学研究中心/中国医学科学院北京协和医学院肿瘤医院肿瘤内科(北京市 100021)

详细信息

通讯作者:
马飞, drmafei@126.com

计量
- 文章访问数: 157
- HTML全文浏览量: 44
- PDF下载量: 38
- 被引次数: 0
出版历程
- 收稿日期: 2020-04-10
- 刊出日期: 2020-12-26

Interpretation of guidelines for the diagnosis and treatment of breast cancer during the COVID-19 outbreak

Lixi Li,
Fei Ma^,

Department of Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China

More Information

Corresponding author: Fei Ma; E-mail:drmafei@126.com

摘要

摘要: 新型冠状病毒肺炎在全球的暴发占用大量医疗资源，极大影响乳腺癌的正常诊疗。乳腺癌患者机体免疫力差，是新型冠状病毒肺炎的易感人群，感染后引发重症的风险极高。如何平衡新型冠状病毒肺炎疫情的有效防控和合理化安排肿瘤诊疗行为，是疫情期间亟待解决的主要临床问题。为此国家肿瘤质控中心乳腺癌专家委员会组织相关领域专家，紧急编撰《新型冠状病毒肺炎疫情期间乳腺癌合理化诊疗指南》，希望为疫情期间乳腺癌诊疗提供科学、可行的解决方案。本文将从乳腺癌诊疗各环节，对指南核心内容进行解读。
- 乳腺肿瘤 /
- 新型冠状病毒肺炎 /
- 诊断 /
- 治疗 /
- 指南
Abstract: The worldwide outbreak of a novel coronavirus (COVID-19) in December 2019 significantly affected the routine diagnosis and treatment of breast cancer due to resource and staffing constraints. In addition, breast cancer patients have poor immunity and are, therefore, more susceptible to COVID-19. If they are infected, the risk of severe illness is extremely high. Therefore, finding a balance between the effective prevention and control of COVID-19 and diagnosing and treating patients with breast cancer is a significant clinical issue during the pandemic. Therefore, the National Cancer Quality Control Center Breast Cancer Expert Committee brought together experts to urgently compile a "Guideline for the Rationalized Diagnosis and Treatment of Breast Cancer during the Outbreak of Corona Virus Disease 2019". Here, we will interpret the core recommendations in the guideline for breast cancer diagnosis and treatment.
- breast neoplasms /
- corona virus disease 2019 (COVID-19) /
- diagnosis /
- treatment /
- guidelines

HTML全文

参考文献(33)

[1]	Hui DS, I Azhar E, Madani TA, et al. The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health-the latest 2019 novel coronavirus outbreak in Wuhan, China[J]. Int J Infect Dis, 2020, 91:264-266. https://www.ncbi.nlm.nih.gov/pubmed/31953166/
[2]	Chinese Center for Disease Control and Prevention. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China[J]. Zhonghua Liu Xing Bing Xue Za Zhi, 2020, 41(2):145-151. http://d.old.wanfangdata.com.cn/Periodical/zhlxbx202002003
[3]	Liang W, Guan W, Chen R, et al. Cancer patients in SARS-CoV-2 infection:a nationwide analysis in China[J]. Lancet Oncol, 2020, 21(3):335-337. http://cn.bing.com/academic/profile?id=c83dc50a2aef37d2056e181e62cb1b84&encoded=0&v=paper_preview&mkt=zh-cn
[4]	国家卫生健康委员会.新型冠状病毒肺炎诊疗方案(试行第七版)[EB/OL].http://www.nhc.gov.cn/yzygj/s7653p/202003/46c9294a7dfe4cef80dc7f5912eb1989.shtml
[5]	中国抗癌协会乳腺癌专业委员会.中国抗癌协会乳腺癌诊治指南与规范(2019年版)[J].中国癌症杂志, 2019, 29(8):609-679. http://d.old.wanfangdata.com.cn/Periodical/zgazzz201908009
[6]	国家卫生健康委员会.医疗机构内新型冠状病毒感染预防与控制技术指南(第一版)[EB/OL].http://www.nhc.gov.cn/yzygj/s7659/202001/b91fdab7c304431eb082d67847d27e14.shtml
[7]	中华人民共和国国家卫生健康委员会.乳腺癌诊疗规范(2018年版)[J].肿瘤综合治疗电子杂志, 2019, 5(3):70-99. http://d.old.wanfangdata.com.cn/Periodical/zlzhzldzzz201903016
[8]	Network NCC. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer (2020 Version 2)[EB/OL]. https://www.nccn.org
[9]	Muhsen S, Moo TA, Patil S, et al. Most breast cancer patients with T1-2 tumors and one to three positive lymph nodes do not need postmastectomy radiotherapy[J]. Ann Surg Oncol, 2018, 25(7):1912-1920. https://www.ncbi.nlm.nih.gov/pubmed/29564588
[10]	McCormick B, Winter K, Hudis C, et al. RTOG 9804:a prospective randomized trial for good-risk ductal carcinoma in situ comparing radiotherapy with observation[J]. J Clin Oncol, 2015, 33(7):709-715. http://cn.bing.com/academic/profile?id=ed12baa7bf9bde85713aded73e9f41d4&encoded=0&v=paper_preview&mkt=zh-cn
[11]	Hershman DL, Wang X, McBride R, et al. Delay in initiating adjuvant radiotherapy following breast conservation surgery and its impact on survival[J]. Int J Radiat Oncol Biol Phys, 2006, 65(5):1353-1360. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=466c60d5513a612f007e7e66c554737b
[12]	Shurell E, Olcese C, Patil S, et al. Delay in radiotherapy is associated with an increased risk of disease recurrence in women with ductal carcinoma in situ[J]. Cancer, 2018, 124(1):46-54. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=10.1002/cncr.30972
[13]	Olivotto IA, Lesperance ML, Truong PT, et al. Intervals longer than 20 weeks from breast-conserving surgery to radiation therapy are associated with inferior outcome for women with early-stage breast cancer who are not receiving chemotherapy[J]. J Clin Oncol, 2009, 27(1):16-23. http://cn.bing.com/academic/profile?id=5a21f7160438013dceef8db9f939cb35&encoded=0&v=paper_preview&mkt=zh-cn
[14]	van Maaren MC, Bretveld RW, Jobsen JJ, et al. The influence of timing of radiation therapy following breast-conserving surgery on 10-year disease-free survival[J]. Br J Cancer, 2017, 117(2):179-188. http://cn.bing.com/academic/profile?id=98035b1e181f7d587b655390ec19a988&encoded=0&v=paper_preview&mkt=zh-cn
[15]	Coles CE, Griffin CL, Kirby AM, et al. Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial):5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial[J]. Lancet, 2017, 390(10099):1048-1060. http://cn.bing.com/academic/profile?id=4f10d0d6d449ac8c4b4e3aade2570804&encoded=0&v=paper_preview&mkt=zh-cn
[16]	Smith BD, Bellon JR, Blitzblau R, et al. Radiation therapy for the whole breast:Executive summary of an American Society for Radiation Oncology (ASTRO) evidence-based guideline[J]. Pract Radiat Oncol, 2018, 8(3):145-152. http://cn.bing.com/academic/profile?id=0f1f4a02762487f7345e9fb6a66bf28d&encoded=0&v=paper_preview&mkt=zh-cn
[17]	Marta GN, Poortmans P. Moderately hypofractionated breast radiation therapy:is more evidence needed[J]?Lancet Oncol, 2019, 20(5):e226. http://cn.bing.com/academic/profile?id=27b32b3c7ad039aacebf5f7c4b7e202e&encoded=0&v=paper_preview&mkt=zh-cn
[18]	Chavez-MacGregor M, Clarke CA, Lichtensztajn DY, et al. Delayed initiation of adjuvant chemotherapy among patients with breast cancer[J]. JAMA Oncol, 2016, 2(3):322-329. http://cn.bing.com/academic/profile?id=89442f90eee9b20e76863e3ec877b011&encoded=0&v=paper_preview&mkt=zh-cn
[19]	Yu KD, Fan L, Qiu LX, et al. Influence of delayed initiation of adjuvant chemotherapy on breast cancer survival is subtype-dependent[J]. Oncotarget, 2017, 8(28):46549-46556. http://cn.bing.com/academic/profile?id=0a5cca15cbfc3e688d9ee6bbcd256654&encoded=0&v=paper_preview&mkt=zh-cn
[20]	Sparano JA, Gray RJ, Makower DF, et al. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer[J]. N Engl J Med, 2018, 379(2):111-121. http://d.old.wanfangdata.com.cn/Periodical/xzyx201903007
[21]	Fujii T, Kogawa T, Dong W, et al. Revisiting the definition of estrogen receptor positivity in HER2-negative primary breast cancer[J]. Ann Oncol, 2017, 28(10):2420-2428. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=5584ab470d357123a498ea9eafbad990
[22]	Munzone E, Colleoni M. Clinical overview of metronomic chemotherapy in breast cancer[J]. Nat Rev Clin Oncol, 2015, 12(11):631-644. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=0bd7469b4107c041157f6184fa2f228a
[23]	Alba E, Calvo L, Albanell J, et al. Chemotherapy (CT) and hormonotherapy (HT) as neoadjuvant treatment in luminal breast cancer patients:results from the GEICAM/2006-03, a multicenter, randomized, phase-II study[J]. Ann Oncol, 2012, 23(12):3069-3074. http://cn.bing.com/academic/profile?id=30e113a4c31f2ac42101733e63224b6f&encoded=0&v=paper_preview&mkt=zh-cn
[24]	Semiglazov VF, Semiglazov VV, Dashyan GA, et al. Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer[J]. Cancer, 2007, 110(2):244-254. http://cn.bing.com/academic/profile?id=5b144745936d81a18fdce5bba00a4813&encoded=0&v=paper_preview&mkt=zh-cn
[25]	Cardoso F, Senkus E, Costa A, et al. 4th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 4)dagger[J].Ann Oncol, 2018, 29(8):1634-1657. https://www.ncbi.nlm.nih.gov/pubmed/30032243
[26]	Ma F, Ouyang Q, Li W, et al. Pyrotinib or lapatinib combined with capecitabine in HER2-positive metastatic breast cancer with prior taxanes, anthracyclines, and/or trastuzumab:a randomized, phase II study[J]. J Clin Oncol, 2019, 37(29):2610-2619. http://cn.bing.com/academic/profile?id=5d69fdc9592664d6d50d949ac64b2faa&encoded=0&v=paper_preview&mkt=zh-cn
[27]	Willemsen AECAB, Tol J, van Erp NP, et al. Prospective study of druginduced interstitial lung disease in advanced breast cancer patients receiving everolimus plus exemestane[J].Target Oncol, 2019, 14(4):441-451. doi: 10.1007/s11523-019-00656-2
[28]	Spiers L, Coupe N, Payne M. Toxicities associated with checkpoint inhibitors-an overview[J]. Rheumatology (Oxford), 2019, 58(Suppl 7):vii7-vii16. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=cb3f0088ef9a8e3cb39fe8e547f3b2bb
[29]	Suresh K, Naidoo J, Lin CT, et al. Immune checkpoint immunotherapy for non-small cell lung cancer:benefits and pulmonary toxicities[J]. Chest, 2018, 154(6):1416-1423. http://cn.bing.com/academic/profile?id=a06694711e067e47c268da9af3f3fe8d&encoded=0&v=paper_preview&mkt=zh-cn
[30]	杨英, 陈显春, 曾令娟, 等.新型冠状病毒肺炎疫情下乳腺癌日间化疗病房运行管理实践[J].中华乳腺病杂志(电子版), 2020, 14(1):E002. http://d.old.wanfangdata.com.cn/Periodical/zhrxbzz202001003
[31]	马飞, 徐兵河, 邵志敏.乳腺癌随访及伴随疾病全方位管理指南[J].中华肿瘤杂志, 2019, 41(1):29-41. http://d.old.wanfangdata.com.cn/Periodical/zhzl201901010
[32]	中华预防医学会妇女保健分会乳腺学组.中国乳腺癌患者生活方式指南[J].全科医学临床与教育, 2017, 15(2):124-128. http://d.old.wanfangdata.com.cn/Periodical/zhwk201702001
[33]	中华医学会肠外肠内营养学分会.肿瘤患者营养支持指南[J].中华外科杂志, 2017, 55(11):801-829. http://d.old.wanfangdata.com.cn/Periodical/zhwk201711001